Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
osimertinib in NSCLC patients at ELCC 2016
.
Show all posts
Showing posts with label
osimertinib in NSCLC patients at ELCC 2016
.
Show all posts
Friday, July 15, 2016
AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016
›
AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with n...
›
Home
View web version
